|
Palo Alto, CA, October 18, 2007 — Telik, Inc. (Nasdaq: TELK) announced that preclinical data from its program to develop novel small molecule kinase inhibitors will be presented at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics in San Francisco. The presentation, “In Vitro and Vivo Anticancer Activities of Dual Inhibitors of Aurora Kinases and VEGFR2” (Abstract# C206) will be on Thursday, October 25, 2007, at 12:30 pm Pacific time during the session “Small Molecule Therapeutic Agents: Kinase Inhibitors.”
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company’s most advanced drug development candidates are TELCYTA®, a tumor-activated small molecule product candidate in clinical development for the treatment of advanced ovarian cancer and non-small cell lung cancer; and TELINTRA™, which is in clinical development for the treatment of myelodysplastic syndrome. Telik’s product candidates were discovered using its proprietary drug discovery technology, TRAP™, which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at www.telik.com
###
Contact:
Carol DeGuzman
Senior Director, Corporate Communications
Telik, Inc.
Tel 650-845-7728
Email cdeguzman@telik.com
Go to: 2007 Press Releases2006
Press Releases
2005
Press ReleasesEvents |
